User:Mr. Ibrahem/Zuclopenthixol
 | |
| Clinical data | |
|---|---|
| Trade names | Clopixol, Cisordinol, others |
| Other names | Zuclopentixol |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | By mouth, IM[1] |
| Drug class | Typical antipsychotic[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 49% (by mouth) |
| Protein binding | 98% |
| Metabolism | Liver (CYP2D6 and CYP3A4-mediated) |
| Elimination half-life | 20 hours (by mouth), 19 days (IM) |
| Excretion | Feces |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H25ClN2OS |
| Molar mass | 400.97 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Zuclopenthixol , sold under the brand names Clopixol among others, is a medication used to treat schizophrenia and other psychoses.[1] Depending on the formulation it may be taken by mouth or by injection into a muscle.[1]
Side effects may include anxiety, depression, high blood sugar, liver problems, sexual dysfunction, and trouble sleeping.[1] Lower doses should be used in those with liver or kidney problems.[1] It is a typical antipsychotic.[1] It may be possible to use the medication while breastfeeding.[4]
Zuclopenthixol was isolated in 1962 and came into medical use in 1978.[5][6] It is approved for use in Australia, Canada, New Zealand, and the UK; though not the United States.[5][7][8] Some forms are available as a generic medication.[1] The long acting decanoate formulation is on the World Health Organization's List of Essential Medicines as an alternative to fluphenazine.[9] In the United Kingdom it is relatively inexpensive as of 2022.[1]
References[edit]
- ^ a b c d e f g h i j k BNF 83 (British National Formulary) March 2022 (83 ed.). Pharmaceutical Press. Aug 13 2022. p. 421. ISBN 9780857114341.
{{cite book}}: Check date values in:|date=(help) - ^ "Clopixol (Zuclopenthixol Hydrochloride) Film-coated tablets". Australian Product Information. Australia: The Therapeutics Goods Administration. Archived from the original on 2018-06-15. Retrieved 2013-08-08.
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ "Zuclopenthixol use while Breastfeeding". Drugs.com. Archived from the original on 24 September 2022. Retrieved 8 September 2023.
- ^ a b Meyer, Jonathan M.; Stahl, Stephen M. (2 September 2021). The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks. Cambridge University Press. p. 201. ISBN 978-1-009-00989-8. Archived from the original on 10 September 2023. Retrieved 8 September 2023.
- ^ Riederer, Peter; Laux, Gerd; Nagatsu, Toshiharu; Le, Weidong; Riederer, Christian (4 November 2022). NeuroPsychopharmacotherapy. Springer Nature. p. 636. ISBN 978-3-030-62059-2. Archived from the original on 10 September 2023. Retrieved 8 September 2023.
- ^ Green AI, Noordsy DL, Brunette MF, O'Keefe C (January 2008). "Substance abuse and schizophrenia: pharmacotherapeutic intervention". Journal of Substance Abuse Treatment. 34 (1): 61–71. doi:10.1016/j.jsat.2007.01.008. PMC 2930488. PMID 17574793.
- ^ Sweetman, Sean C., ed. (2009). "Anxiolytic Sedatives Hypnotics and Antipsychotics". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1040–1. ISBN 978-0-85369-840-1.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.